PepGen (PEPG) Depreciation & Amortization (CF) (2021 - 2026)
PepGen (PEPG) posted Depreciation & Amortization (CF) of $300000.0 for Q1 2026, little changed sequentially from $300000.0 in Q4 2025, and down 25.0% YoY from $400000.0 in Q1 2025.
Powered by 
Analysis
PepGen (PEPG) Depreciation & Amortization (CF) (2021 - 2026) Analysis & Trends
PepGen has reported Depreciation & Amortization (CF) for 6 years, with the latest figure at $300000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) fell 25.0% year-over-year to $300000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 25.0% YoY) and the FY2025 annual result came in at $1.4 million, down 6.67% from the prior year.
- Depreciation & Amortization (CF) was little changed at $300000.0 in Q1 2026 per PEPG's latest filing, from $300000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $400000.0 in Q4 2023 and troughed at $100000.0 in Q1 2022.
- A 5-year average of $288235.3 and a median of $300000.0 in 2023 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2023 and 2025: Depreciation & Amortization (CF) jumped 200.0% in 2023, then slipped 25.0% in 2025.
- Over 5 years, Depreciation & Amortization (CF) stood at $200000.0 in 2022, then surged by 100.0% to $400000.0 in 2023, then changed by 0.0% to $400000.0 in 2024, then retreated by 25.0% to $300000.0 in 2025, then changed by 0.0% to $300000.0 in 2026.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $300000.0, $300000.0, and $300000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | PepGen | 217.99 Mn | 217.99 Mn | - | 300,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300,000.00 |
| Mar 31, 2026 | 300,000.00 |
| Dec 31, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Jun 30, 2025 | 300,000.00 |
| Mar 31, 2025 | 400,000.00 |
| Dec 31, 2024 | 400,000.00 |
| Sep 30, 2024 | 400,000.00 |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 400,000.00 |
| Dec 31, 2023 | 400,000.00 |
| Sep 30, 2023 | 300,000.00 |
| Jun 30, 2023 | 300,000.00 |
| Mar 31, 2023 | 200,000.00 |
| Dec 31, 2022 | 200,000.00 |
| Sep 30, 2022 | 100,000.00 |
| Jun 30, 2022 | 100,000.00 |
| Mar 31, 2022 | 100,000.00 |
| Dec 31, 2021 | 100,000.00 |
| Sep 30, 2021 | 100,000.00 |